South Korea's LG Takes Shot At Vaccines Via In-licensing Deal With U.S. Novavax

SEOUL - South Korea's LG Life Sciences said next year it will start building a production plant in Osong, south of the capital city of Seoul, to produce cell-culture influenza vaccines based on the virus-like particle technology in-licensed from Novavax of the U.S